RecruitingAlzheimer Disease
Late Onset Alzheimer's Disease
Eligible age
55+ yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Sponsor: Columbia University
You may qualify if…
- ✓ Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
- ✓ a living sibling with probable or possible AD;
- ✓ a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
- ✓ participants in the proband's generation with an identified companion serving as an informant;
- ✓ participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.
You may not qualify if…
- ✕ failure to identify an appropriate informant;
- ✕ uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
- ✕ discovery of additional diagnosis that could account for the clinical manifestations;
- ✕ unwillingness to participate;
- ✕ failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
- ✕ participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Where it's recruiting
District of Columbia
Washington D.C.
Florida
Miami
Illinois
Aurora
Indiana
Bloomington · Indianapolis
Minnesota
Rochester
Missouri
St Louis
New York
New York
North Carolina
Raleigh
Pennsylvania
Pittsburgh
Texas
Dallas
Washington
Seattle
Source: ClinicalTrials.gov · NCT05010603 · last updated 2026-05-18